KT Medical Service PCL vs Encompass Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

KT Medical Service PCL (KTMS.BK)

Q3 202619 Aug – 4 Oct 2026

▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.
It shows the main business is growing and expanding, directly driving future revenue and profit.
High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.
It explains the underlying demand that supports KTMS's expansion and revenue targets.
Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.
It is a real counterweight that could slow near-term revenue recognition and pressure the stock.
Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.
It gives a forward-looking positive catalyst that could drive the stock higher.

September 202619 Aug – 4 Oct 2026

▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.
It shows the main business is growing and expanding, directly driving future revenue and profit.
High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.
It explains the underlying demand that supports KTMS's expansion and revenue targets.
Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.
It is a real counterweight that could slow near-term revenue recognition and pressure the stock.
Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.
It gives a forward-looking positive catalyst that could drive the stock higher.

Latest19 Aug – 4 Oct 2026

▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.
It shows the main business is growing and expanding, directly driving future revenue and profit.
High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.
It explains the underlying demand that supports KTMS's expansion and revenue targets.
Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.
It is a real counterweight that could slow near-term revenue recognition and pressure the stock.
Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.
It gives a forward-looking positive catalyst that could drive the stock higher.

Encompass Health Corp (EHC)

Q3 20261 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.

August 20261 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.

Latest1 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.